menu search

CLNN / Clene Inc. (CLNN) Reports Q1 Loss, Misses Revenue Estimates

Clene Inc. (CLNN) Reports Q1 Loss, Misses Revenue Estimates
Clene Inc. (CLNN) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.21 per share a year ago. Read More
Posted: May 12 2023, 19:01
Author Name: Zacks Investment Research
Views: 110281

CLNN News  

Clene to Present at Upcoming September Conferences

By GlobeNewsWire
August 30, 2023

Clene to Present at Upcoming September Conferences

SALT LAKE CITY, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary more_horizontal

Clene Inc. (CLNN) Reports Q1 Loss, Misses Revenue Estimates

By Zacks Investment Research
May 12, 2023

Clene Inc. (CLNN) Reports Q1 Loss, Misses Revenue Estimates

Clene Inc. (CLNN) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $ more_horizontal

Clene to Announce New CNM-Au8® Data From the Healey ALS Platform Trial

By GlobeNewsWire
March 8, 2023

Clene to Announce New CNM-Au8® Data From the Healey ALS Platform Trial

Webcast set for 7:30 a.m. ET on March 9 Webcast set for 7:30 a.m. ET on March 9 more_horizontal

Clene to Present at Upcoming September Investor Conferences

By GlobeNewsWire
August 30, 2022

Clene to Present at Upcoming September Investor Conferences

SALT LAKE CITY, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Clene Inc.  (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary more_horizontal

Why Shares of Clene Jumped 11.8% on Monday

By The Motley Fool
July 18, 2022

Why Shares of Clene Jumped 11.8% on Monday

The company's lead therapy has shown progress against ALS in preliminary trials. more_horizontal

HC Wainwright Initiates Coverage On This Nanocrystals Stock

By Benzinga
July 18, 2022

HC Wainwright Initiates Coverage On This Nanocrystals Stock

H.C. Wainwright initiated coverage on Clene Inc (NASDAQ: CLNN) with a Buy rating and a $16 price target.  Clene is focused on the development of more_horizontal

Why Is Clene (CLNN) Stock Soaring 23% Today?

By InvestorPlace
July 14, 2022

Why Is Clene (CLNN) Stock Soaring 23% Today?

Clene (CLNN) stock is heading higher on Thursday following the release of data from a long-term clinical trial of CNM-Au8. The post Why Is Clene (CLNN more_horizontal


Search within

Pages Search Results: